PYXS Pyxis Oncology, Inc.
USHealthcareAs of 2026-07-10 16:00
Why PYXS matters now
Pyxis Oncology, Inc. (PYXS) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.67 with +1.14% on the session and $169.2M in market capitalization; recent performance reads 1-month +6.28% and YTD +76.52%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-23.3M, and EPS of $-0.37. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -52.1%.
The latest indexable market news headline is "Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.00; recent insider activity includes Palani Santhosh filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.12
P/S
9.28
EV/EBITDA
-1.84
DCF Value
$1.74
FCF Yield
-52.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.8%
Operating Margin
-619.6%
Net Margin
-589.8%
ROE
-135.6%
ROA
-127.1%
ROIC
-173.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-23.3M | $-0.37 |
| Q4 2025 | $11.0M | $-18.1M | $-0.29 |
| FY 2025 | $13.9M | $-79.6M | $-1.28 |
| Q3 2025 | $0.00 | $-22.0M | $-0.35 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$6.00
Target (Median)
$6.00
Target Range
$6.00 - $6.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.43
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.